Ezgi Ulas, PhD candidate at Amsterdam UMC, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“New publication in Journal for ImmunoTherapy of Cancer!
Happy to share our recent study on the immune-modulating effects in tumor-draining lymph nodes (TDLN) of patients with T3-4N0-2 non-small cell lung cancer.
Highlights:
- Active proliferation of CD8⁺ T cells and regulatory T cells with enhanced type I immune responses were observed within TDLN when dual immunotherapy was added to neoadjuvant chemoradiotherapy, irrespective of received radiation dose
- High radiation led to increased fibrosis and prolonged inflammation in TDLN, while immune responses remained preserved compared with low dose TDLN
These findings add to the discussion on the impact of radiation to the TDLN and underscore the importance of their immunological function in multimodality treatment strategies
Thanks to all co-authors and collaborators for the great teamwork behind this project!”
Title: Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC
Authors: Ezgi B. Ulas, Sofie J. I. Koomen, Anne Vrijmoet, Ilias Houda, H. Ibrahim Korkmaz, Chris Dickhoff, Idris Bahce, Suresh Senan, Tanja D. de Gruijl, Marieke F. Fransen, Teodora Radonic, Febe van Maldegem, Famke L. Schneiders
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts about NSCLC.
